Search | Clinical Trials Finder

Conditions: Prostate Cancer
Interventions: ES414; Biological
Lead sponsor: Aptevo Therapeutics; Industry
Eligibility: Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: San Francisco, California • Buffalo, New York • Temple, Texas + 1 more

Conditions: Aplastic Anemia
Interventions: Campath-1H, r-ATG, CsA; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions: Datopotamab Deruxtecan; Drug
Lead sponsor: Nancy Lin, MD; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Immunologic Deficiency Syndrome
Interventions: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™; Drug
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more

Conditions: Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions: Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P; Diagnostic Test · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Interventions: 4A10; Drug
Lead sponsor: Allterum Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Pancreatic Adenocarcinoma
Interventions: 9-ING-41, Retifanlimab, Gemcitabine, Abraxane; Drug
Lead sponsor: Anwaar Saeed; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Fairway, Kansas • Pittsburgh, Pennsylvania

Conditions: Asthma
Interventions: Placebo, Benralizumab; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 9
States / cities: Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more

Conditions: Breast Cancer
Interventions: trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Fort Myers, Florida • Detroit, Michigan • Portland, Oregon + 1 more

Conditions: Colorectal Cancer
Interventions: Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX), Leucovorin (in FOLFOX), Oxaliplatin (in FOLFOX); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 44
States / cities: Anniston, Alabama • Birmingham, Alabama • Casa Grande, Arizona + 41 more

Conditions: Lymphocytic Leukemia, Chronic
Interventions: obinutuzumab, rituximab, chlorambucil; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W); Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more

Conditions: HIV-1 Infection
Interventions: 3BNC117, Antiretroviral Treatment Interruption; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma
Interventions: INBRX-105 - PDL1x41BB antibody, Pembrolizumab; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 23
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal Saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota

Conditions: Renal Cell Carcinoma
Interventions: Atezolizumab, Bevacizumab, RO6874281; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland

Conditions: Hepatocellular Carcinoma
Interventions: Atezolizumab, Bevacizumab, Tiragolumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more

Conditions: Breast Cancer
Interventions: Trastuzumab, Oxaliplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 7
States / cities: Bowling Green, Kentucky • Alexandria, Louisiana • Baton Rouge, Louisiana + 4 more

Conditions: Pancreatitis, Chronic; Diabetes; Transplant
Interventions: etanercept, Alpha 1-Antitrypsin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Prostate Cancer
Interventions: AZD0516, AZD9574; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more

Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab; Biological
Lead sponsor: Simcha IL-18, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Graft Versus Host Disease
Interventions: Natalizumab, Methylprednisolone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Ureteral Cancer, Urothelial Cancer, Bladder Cancer
Interventions: Enfortumab Vedotin, Docetaxel, Vinflunine, Paclitaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 25
States / cities: Orange, California • Sacramento, California • Whittier, California + 21 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions: CC-90002; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 6
States / cities: Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more

Search by objective public record fields.

Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

A Study of the Safety and Antiretroviral Activity of 3BNC117

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)